“We had a good meeting; he was a good dude,” Washington said. “Got a lot to understand about what’s going on.”Washington, 26, made the Pro Bowl last season after racking up 134 total tackles to go along with nine sacks, one interception, two forced fumbles and one fumble recovery. One of the best young linebackers in the NFL, his offseason was marred by the suspension as well as an arrest on domestic violence charges.His next court date is scheduled for Oct. 9, and whether or not that will lead to him missing more games remains to be seen. In the meantime, Washington, who missed practice Tuesday to go to the Big Apple, will just keep working to get his career back on track.Saying the meeting was worthwhile if only to allow the league executive see what kind of person he was off the field, all the linebacker can do is move forward. “I’m going to keep my head up, put a smile on my face and be ready to play.” – / 31 Derrick Hall satisfied with D-backs’ buying and selling Daryl Washington was hoping for a better result of a trip to New York to meet with NFL executives about his four-game suspension.“I thought it was a good interview in New York but I didn’t get the news I wanted to here,” the linebacker said Thursday. “I think that’s just motivation for me to come back stronger (after) these four games.”Washington, who was suspended for a quarter of the regular season for violating the league’s substance abuse policy back in April, wanted to talk with NFL Commissioner Roger Goodell about the matter, but instead met with the league’s Vice President for Law and Labor Policy, Dr. Adolpho Birch. Top Stories 0 Comments Share Former Cardinals kicker Phil Dawson retires The 5: Takeaways from the Coyotes’ introduction of Alex Meruelo Grace expects Greinke trade to have emotional impact
Source:https://newsroom.uvahealth.com/2018/05/07/hemoshear-cancer-model/ May 7 2018A scientist at the University of Virginia School of Medicine, working with local biotech company HemoShear Therapeutics, has created a three-dimensional model of a cancer tumor that he says has the potential to replicate the complex nature and behavior of a real tumor. The model will help researchers better understand the disease and accelerate the development of new and better treatments.The multicellular model also can be customized to behave like a particular patient’s tumor, so that doctors can determine how the tumor will react to different drugs. That could allow them to identify the best treatment option based on a simple biopsy.”This model enables us to understand the inner workings of tumors to systematically identify and test new ways to treat cancer,” said researcher Dan Gioeli, PhD, of UVA’s Department of Microbiology, Immunology and Cancer Biology and the UVA Cancer Center.Related StoriesTrends in colonoscopy rates not aligned with increase in early onset colorectal cancerLiving with advanced breast cancerStudy reveals link between inflammatory diet and colorectal cancer riskBetter Understanding CancerThe new model mimics the tumor “microenvironment” for pancreatic cancer and non-small cell lung carcinoma. It could, however, benefit the battle against many types of solid tumors, Gioeli said. The model will enable scientists to better understand how cancer takes root and how the cancer cells grow, spread and develop resistance to treatment.Gioeli’s model, made in collaboration with HemoShear, reflects the complexities of cancer by incorporating different cell types that are found in tumors. For example, it includes vascular endothelial cells, the cells that line blood vessels and are exposed to the tremendous shearing forces of blood flow.Researchers will be able to manipulate the different components of the model in a way not possible with existing methods, according to HemoShear. This should provide important insights during the development of new treatments, Gioeli said.”This model incorporates tumor hemodynamics and biological transport in a way that other tumor models do not,” he said. “We believe this model can be used for the rapid evaluation of novel precision therapies.”Cancer Model UnveiledGioeli will present the new model in Boston this week at a scientific meeting, 3D Tissue Models Oncology 2018.Gioeli has worked as senior director of cancer biology at Charlottesville-based HemoShear while on sabbatical from UVA. He has a financial stake in the company.HemoShear’s core technology was originally developed by two UVA researchers to create more accurate models of human disease for deeper understanding of how diseases develop and to discover safer and more effective drug therapies.